1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Changchun High-Tech Industry (Group) Co., Ltd. Class A

Changchun High-Tech Industry (Group) Co., Ltd. Class A

SSZSE:000661
72.08
CNY
+3.69
(+5.40%)
-0.46EPS
27.17BMarket Cap
Oct 30Next Earn
Changchun High-Tech Industry (Group) Co., Ltd. Class A
SZSE:000661
(Shenzhen Stock Exchange)

Recent

price

72.08

P/E

ratio

- -

div

yld

0.36%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
3.88
4.27
5.84
6.79
7.5
9.15
9.2
12.05
15.81
42.66
21.2
26.54
31.38
36.03
33.47
30.41
28.46
Revenue per Share
0.29
0.36
0.99
0.94
1.05
1.47
1.54
1.95
2.96
10.27
7.53
9.28
10.29
11.21
6.42
0.39
-0.06
Basic EPS, GAAP
0.73
-0.1
0.78
0.9
0.59
2.07
0.39
0.44
0.58
6.31
0.03
2.72
1.83
7.44
2.29
-3.52
- -
Free Cash Flow per Basic Share
0.09
0.11
0.18
0.13
0.2
0.21
0.33
0.46
0.4
0.69
0.53
0.76
1.22
1.08
4.57
2.73
0.26
Dividend per Share
1.73
2.09
3.08
3.95
4.84
5.9
11.46
13.01
15.6
19.98
27.01
36.01
44.6
54.55
56.37
53.95
54.94
Book Value per Share
1.4
1.6
2.59
3.47
4.32
5.19
10.61
12.09
14.49
18.86
23.96
31.35
38.92
47.31
47.93
44.72
46.1
Tangible Book Value per Share
301
303
302
302
302
262
315
340
340
173
405
405
402
404
402
397
401
Basic Weighted Avg Shares
1,166
1,295
1,761
2,049
2,262
2,402
2,897
4,102
5,375
7,374
8,577
10,747
12,627
14,566
13,466
12,083
11,425
Sales/Revenue/Turnover
19.69
17.18
23.97
25.69
23.6
25.95
27.54
27.62
32.12
37.89
44.9
44.52
40.2
39.92
27.41
7.2
5.18
Operating Margin (%)
45
46
56
63
72
77
82
85
103
143
174
299
435
549
621
761
- -
Depreciation Expense
86
110
300
284
318
384
485
662
1,006
1,775
3,047
3,757
4,141
4,532
2,583
155
-24
Net Income, GAAP
28.92
23.42
15.57
18.74
15.6
17.48
17.16
17.08
15.59
16.7
15.48
15.58
14.4
13.33
13.75
5,184.02
- -
Effective Tax Rate (%)
7.42
8.46
17.02
13.86
14.06
16.01
16.73
16.14
18.73
24.07
35.52
34.96
32.79
31.12
19.18
1.28
-0.21
Profit Margin (%)
261
193
396
673
906
1,061
2,829
3,284
3,632
5,524
7,592
10,265
11,488
13,366
12,851
10,139
9,567
Working Capital
16
16
6
21
20
24
8
12
12
68
817
1,206
1,130
670
1,274
1,255
314
LT Debt
804
946
1,304
1,703
2,045
2,435
4,450
5,200
6,342
8,808
12,323
17,237
20,805
25,032
26,102
24,870
25,224
Total Equity
16.46
14.51
30.05
26.85
22.56
21.7
18.77
19.08
25.51
29.73
28.32
24.15
20.56
19.7
10.43
-73.37
- -
Return on Invested Capital (%)
5.53
6.13
15.8
9.37
9.89
10
8.39
8.18
9.39
15.09
24.25
22.37
20
17.73
9.2
-6.85
- -
Return on Capital (%)
18.06
19.03
38.47
26.76
23.99
23.75
17.08
15.9
20.68
26.51
32.04
29.46
25.38
22.59
11.46
0.69
-0.11
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
682
726
1,970
LT Borrowings
1,234
1,249
293
LT Finance Leases
21
22
21
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
408
408
408
Market Capitalization
37,755
35,030
27,169

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
13,809
14,351
14,427
Cash, Cash Equivalents & STI
3,595
4,312
4,882
Accounts Receivable, Net
2,031
2,088
1,890
Inventories
5,833
5,770
5,826
Total Current Liabilities
3,669
4,079
4,860
Payables & Accruals
- -
- -
- -
ST Debt
682
726
1,970
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
28.08%
16.09%
-4.72%
Free Cash Flow
811.11%
1,556.73%
-251.72%
Net Income, GAAP
16.87%
-18.8%
-94%
Sales/Revenue/Turnover
18.71%
8.07%
-10.27%
Total Cash Common Dividend
56.4%
73.98%
-41.06%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,177
3,461
3,749
3,078
13,466
2025
2,997
3,605
- -
2,277
12,083
2026
2,587
2,955
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.13
2.15
2.69
-0.51
6.42
2025
1.17
1.27
- -
-2.51
0.39
2026
0.69
0.5
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
4.52
0.04
0.01
4.57
2025
0.02
0.02
- -
0.02
2.73
2026
0.03
0.19
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Amgen Inc. (NASDAQ:AMGN)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
Kodiak Sciences Inc (NASDAQ:KOD)
Business
Changchun High-Tech Industries (Group) Inc. (000661.SZ) is a leading Chinese biotechnology company focused on the research, development, manufacture, and commercialization of human vaccines and biological products. The company offers a comprehensive portfolio of vaccines including live attenuated measles vaccine, live attenuated measles-rubella combined vaccine, live attenuated mumps vaccine, live attenuated measles-mumps-rubella combined vaccine under the Hong Yi brand, recombinant hepatitis B vaccine under the Ye Lai Kang brand, bivalent human papillomavirus vaccine under the Kang Hui brand, and tetanus toxoid vaccine; it also provides biological products such as human rabies vaccine and varicella vaccine, alongside contract development and manufacturing services for biologics. Changchun High-Tech operates primarily in the pharmaceutical and healthcare sectors, targeting domestic and international markets with a focus on immunization programs for children and adults, and maintains production facilities and research centers in China. Founded in 1995 and headquartered in Changchun, Jilin Province, China, the company conducts its operations predominantly within the People's Republic of China, with distribution networks extending to select international regions through partnerships. As a key player in China's vaccine industry, it serves government procurement programs, hospitals, and public health initiatives, emphasizing innovation in recombinant and attenuated vaccine technologies. In recent developments, Changchun High-Tech has advanced its product pipeline with regulatory approvals for new indications and expansions, including the commercial launch of its bivalent HPV vaccine targeting high-risk strains prevalent in Asia; the company also completed strategic investments in R&D facilities to enhance capacity for mRNA-based vaccines amid global demand surges post-2023. Additionally, it formed alliances with international biotech firms for technology transfers in next-generation rabies and combination vaccines, while securing funding through equity offerings to support Phase III trials for a novel rotavirus vaccine in late 2024. These initiatives reflect ongoing expansions into preventive healthcare segments and strengthened compliance with global cGMP standards.